"Precision medicine and targeted therapies have played a crucial role over the past ten years in the personalized care of cancer patients. In this retrospective and observational study, we focused on patients for which no standard or curative treatment was available and for which the management was discussed in a Molecular Tumor Board (MTB).

The role of the MTB is to decide the most appropriate therapeutic options for patients according to the potential identification of molecular targets.

Among the analyses carried out, we focused on a quantitative genome-wide analysis: the CGH/SNP-array (Comparative Genomic Hybridization / Single Nucleotide Polymorphism on array). The objective was to evaluate the impact of CGH/SNP-array analyses in the identification of targeted molecular alterations.

"

Inclusion Criteria:

• Histologically or cytologically confirmed solid tumor malignancy that is advanced or metastatic ;
• no standard or curative treatment available;
• non-opposition of the patient collected.

Exclusion Criteria:

• multiple cancer patient;
• ECOG Scale of Performance Status (PS) ≥2

Cancer patients for which no standard or curative treatment was available and for which the personalized management was discussed in a Molecular Tumor Board.